ClouDr Group Integrates DeepSeeker R1 into CloudrBrain to Boost Chronic Disease Management
China-based ClouDr Group Limited (HKG: 9955) announced the integration of the DeepSeeker R1 model into...
Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...
Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378
China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...
Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms
China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...
Becton Dickinson Considers Spinning Off Life Sciences Division
US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division,...
Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition
Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone...
Nona Biosciences Partners with Invetx for Animal Health Therapies
Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...
AbbVie Reports Strong Q4 and Full-Year 2024 Financials
US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...
IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...
Novartis Reports 12% YOY Growth in Full-Year Net Sales
Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report,...
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period...
Daiichi Sankyo Reports 16.6% Revenue Growth in First Three Quarters of FY2024
Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for...
Pfizer Reports 7% Revenue Growth in 2024, Expects Steady Performance in 2025
US major Pfizer Inc. (NYSE: PFE) has released its financial results for the fourth quarter...
China’s MoC Lists US Firms PVH and Illumina as Unreliable Entities
China’s Ministry of Commerce (MoC) has released a list of unreliable entities, including US firms...
Roche Reports 7% Growth in Full-Year Sales, Strength in Pharmaceuticals
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q4 and full-year 2024 financials, reporting a...
Sanofi Reports Strong Q4 Growth, Plans EUR 5 Billion Share Buyback
French pharmaceutical giant Sanofi (NASDAQ: SNY) reported a strong fourth-quarter performance with 10.3% year-on-year (YOY)...
Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered...
DeepSeek’s AI: Transforming Drug Development and Healthcare in China
DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the...
MediLink Therapeutics’ YL217 Receives FDA IND Clearance for Novel ADC Targeting Gastrointestinal Cancers
MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC),...
AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with...